Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR2 N549K PRN1371 endometrial adenocarcinoma sensitive detail...
AKT1 E17K Capivasertib endometrial adenocarcinoma predicted - sensitive detail...
BRCA2 S1982Rfs*22 BRCA2 K2547Nfs*4 Olaparib endometrial adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01482728 Phase I Dasatinib Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer Completed
NCT01877564 Phase II Metformin A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women Completed
NCT02065687 Phase III Carboplatin + Metformin + Paclitaxel Carboplatin + Paclitaxel Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting
NCT02178722 Phase Ib/II Pembrolizumab Epacadostat A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037) Active, not recruiting
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Recruiting
NCT02208375 Phase Ib/II Olaparib Capivasertib Vistusertib mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer Active, not recruiting
NCT02335203 Phase II Medroxyprogesterone The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy Unknown status
NCT02697591 Phase Ib/II INCAGN01876 An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors Recruiting
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting
NCT02923349 Phase Ib/II INCAGN01949 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed
NCT03018249 Phase II Medroxyprogesterone Entinostat + Medroxyprogesterone Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer Active, not recruiting
NCT03120624 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Suspended
NCT03345784 Phase I Adavosertib + Cisplatin WEE1 Inhibitor AZD1775, External Beam Radiation Therapy, and Cisplatin in Treating Patients With Cervical, Vaginal, or Uterine Cancer Recruiting
NCT03348631 Phase II Tazemetostat Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer Recruiting
NCT03586661 Phase I Copanlisib + Niraparib Niraparib and Copanlisib in Treating Participants With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Not yet recruiting
NCT03660826 Phase II Olaparib Cediranib + Olaparib Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer Recruiting
NCT03694262 Phase II Atezolizumab + Bevacizumab + Rucaparib The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (EndoBARR) Not yet recruiting
NCT03832361 Phase II Mirvetuximab Soravtansine Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-alpha Positive Endometrial Cancer Not yet recruiting